Post by ronw77077 on Feb 16, 2024 16:05:27 GMT -5
Not sure where to post this, but good article about MNKD in Entrepreneur Magazine - see MNKD text below
3 Biotech Stocks Investors Are Watching for Future Growth
A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry's bright...
A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry's bright..
.
A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry's bright outlook, biotech stocks MannKind (MNKD), Illumina (ILMN), and TG Therapeutics (TGTX) could be ideal watchlist additions for potential growth. Read on….
From healthcare and industrial processing to food and agriculture, biotechnology has touched every aspect of life, thereby improving human and animal health and the environment. Furthermore, the biotech industry's expansion is fueled by favorable government policies and emerging technological developments.
Given the industry's strong foothold, it could be wise to watch biotech stocks MannKind Corporation (MNKD), Illumina, Inc. (ILMN), and TG Therapeutics, Inc. (TGTX) for future growth.
Biotechnology has a wide range of applications in various sectors, particularly in medicine, agriculture, and industrial processing. Favorable government funding and policies would primarily propel the industry's growth. In the past few years, there has been a rise in the prevalence of chronic diseases, mainly due to rapid urbanization and an increasingly sedentary lifestyle.
The biopharmaceuticals market is projected to reach $761.80 billion by 2029, growing at a CAGR of 8.1%. The rise in the need for personalized medicine and the growing portfolio of orphan drug formulations contribute to the market's expansion. In 2023, the FDA's Center for Drug Evaluation and Research (CDER) approved 55 new molecular entities and therapeutic biological products.
Moreover, the surging demand for biotechnology tools in agricultural applications such as tissue culturing, molecular breeding, and micro-propagation would create several opportunities for the industry players. Besides, the rising popularity of genetically modified crops, seeds, and herbicide-tolerant crops would further contribute to the sector's expansion.
The biotechnology industry stands at a pivotal point, driven by numerous technological advancements and evolving market dynamics. Key market trends include the progression of AI in drug discovery, RNA technology sophistication, the development of CRISPR technology, and significant advancements in stem cell technology and targeted protein degradation.
This year, bioprinting and tissue engineering are expected to be significant trends shaping the bioengineering industry. These technologies would offer promising prospects for medical applications. The tissue engineering market is estimated to reach $8.90 billion by 2028, growing at a CAGR of 15.3%.
According to a report by Grand View Research, the global biotechnology market is predicted to total $3.88 trillion by 2030, expanding at a robust CAGR of 14% during the forecast period (2024-2030).
Further, investors' interest in biotech stocks is evident from SPDR S&P Biotech ETF's (XBI) 31.6% returns over the past three months.
Considering these favorable trends, let's look at the fundamentals of the three Biotech stocks, beginning with the third choice.
Stock #3: MannKind Corporation (MNKD)
MNKD is a biopharmaceutical company that focuses on developing and commercializing inhaled therapeutic products for endocrine and orphan lung diseases. The company provides Afrezza, an inhaled insulin to treat diabetes, and the V-Go wearable insulin delivery device. Its product pipeline also includes Tyvaso DP Treprostinil and MNKD-101.
On January 2, 2024, MNKD and Sagard Healthcare entered an agreement under which MannKind sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder to Sagard in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.
United Therapeutics Corporation licensed Tyvaso DPI from MNKD in 2018. It began marketing it in June 2022 after FDA approval for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Pursuant to a license agreement with United Therapeutics, MannKind is entitled to a 10% royalty on net sales of Tyvaso DPI.
On October 30, 2023, MNKD announced a new patent (No. 11,793,808) issued by the United States Patent and Trademark Office covering clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease. The patent is expected to expire on June 8, 2039.
This patent represents important protection for MNKD's lead pipeline asset, MNKD-101, which could potentially enhance therapy for a lung disease that is on the rise globally.
MNKD's trailing-12-month gross profit margin of 65.55% is 15.2% higher than the industry average of 56.91. However, the stock's trailing-12-month EBITDA and net income margin of negative 1.5% and negative 17.7% compared to the respective industry averages of 5.09% and 0.19%.
Over the past three years, MNKD's revenue has grown at a CAGR of 41.2%. The company's total assets have improved at a CAGR of 49.6% over the same period.
In the third quarter that ended September 30, 2023, MNKD's revenues increased 56.1% year-over-year to $51.25 million. Its net revenue from Afrezza grew 24%, but net revenue from V-Go declined 18%. Its non-GAAP income from operations came in at $7.63 million, compared to a loss from operations of $7.79 million in the prior year's quarter.
In addition, the company's non-GAAP net income amounted to $4.26 million, or $0.01 per share, compared to a net loss of $12.61 million, or $0.06 per share, in the same quarter of 2022, respectively.
Street expects MNKD's revenue for the fiscal year (ended December 2023) to increase 94.1% year-over-year to $193.64 million. However, analysts estimate that the company will report a loss per share of $0.05 for the same period.
Shares of MNKD have gained 1.8% over the past five days to close the last trading session at $3.41.
MNKD's mixed prospects are apparent in its POWR Ratings. The stock has an overall rating of C, which translates to a Neutral in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
MNKD has an A grade for Growth and a B for Value. It also has a C grade for Sentiment and Quality. It has ranked #40 out of 349 stocks in the Biotech industry.
Click here to see the other ratings of MNKD for Momentum and Stability.
About the Author: Mangeet Kaur Bouns
Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.
3 Biotech Stocks Investors Are Watching for Future Growth
A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry's bright...
A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry's bright..
.
A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry's bright outlook, biotech stocks MannKind (MNKD), Illumina (ILMN), and TG Therapeutics (TGTX) could be ideal watchlist additions for potential growth. Read on….
From healthcare and industrial processing to food and agriculture, biotechnology has touched every aspect of life, thereby improving human and animal health and the environment. Furthermore, the biotech industry's expansion is fueled by favorable government policies and emerging technological developments.
Given the industry's strong foothold, it could be wise to watch biotech stocks MannKind Corporation (MNKD), Illumina, Inc. (ILMN), and TG Therapeutics, Inc. (TGTX) for future growth.
Biotechnology has a wide range of applications in various sectors, particularly in medicine, agriculture, and industrial processing. Favorable government funding and policies would primarily propel the industry's growth. In the past few years, there has been a rise in the prevalence of chronic diseases, mainly due to rapid urbanization and an increasingly sedentary lifestyle.
The biopharmaceuticals market is projected to reach $761.80 billion by 2029, growing at a CAGR of 8.1%. The rise in the need for personalized medicine and the growing portfolio of orphan drug formulations contribute to the market's expansion. In 2023, the FDA's Center for Drug Evaluation and Research (CDER) approved 55 new molecular entities and therapeutic biological products.
Moreover, the surging demand for biotechnology tools in agricultural applications such as tissue culturing, molecular breeding, and micro-propagation would create several opportunities for the industry players. Besides, the rising popularity of genetically modified crops, seeds, and herbicide-tolerant crops would further contribute to the sector's expansion.
The biotechnology industry stands at a pivotal point, driven by numerous technological advancements and evolving market dynamics. Key market trends include the progression of AI in drug discovery, RNA technology sophistication, the development of CRISPR technology, and significant advancements in stem cell technology and targeted protein degradation.
This year, bioprinting and tissue engineering are expected to be significant trends shaping the bioengineering industry. These technologies would offer promising prospects for medical applications. The tissue engineering market is estimated to reach $8.90 billion by 2028, growing at a CAGR of 15.3%.
According to a report by Grand View Research, the global biotechnology market is predicted to total $3.88 trillion by 2030, expanding at a robust CAGR of 14% during the forecast period (2024-2030).
Further, investors' interest in biotech stocks is evident from SPDR S&P Biotech ETF's (XBI) 31.6% returns over the past three months.
Considering these favorable trends, let's look at the fundamentals of the three Biotech stocks, beginning with the third choice.
Stock #3: MannKind Corporation (MNKD)
MNKD is a biopharmaceutical company that focuses on developing and commercializing inhaled therapeutic products for endocrine and orphan lung diseases. The company provides Afrezza, an inhaled insulin to treat diabetes, and the V-Go wearable insulin delivery device. Its product pipeline also includes Tyvaso DP Treprostinil and MNKD-101.
On January 2, 2024, MNKD and Sagard Healthcare entered an agreement under which MannKind sold a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder to Sagard in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.
United Therapeutics Corporation licensed Tyvaso DPI from MNKD in 2018. It began marketing it in June 2022 after FDA approval for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Pursuant to a license agreement with United Therapeutics, MannKind is entitled to a 10% royalty on net sales of Tyvaso DPI.
On October 30, 2023, MNKD announced a new patent (No. 11,793,808) issued by the United States Patent and Trademark Office covering clofazimine inhalation suspension (MNKD-101), which is under development for the potential treatment of nontuberculous mycobacterial (NTM) lung disease. The patent is expected to expire on June 8, 2039.
This patent represents important protection for MNKD's lead pipeline asset, MNKD-101, which could potentially enhance therapy for a lung disease that is on the rise globally.
MNKD's trailing-12-month gross profit margin of 65.55% is 15.2% higher than the industry average of 56.91. However, the stock's trailing-12-month EBITDA and net income margin of negative 1.5% and negative 17.7% compared to the respective industry averages of 5.09% and 0.19%.
Over the past three years, MNKD's revenue has grown at a CAGR of 41.2%. The company's total assets have improved at a CAGR of 49.6% over the same period.
In the third quarter that ended September 30, 2023, MNKD's revenues increased 56.1% year-over-year to $51.25 million. Its net revenue from Afrezza grew 24%, but net revenue from V-Go declined 18%. Its non-GAAP income from operations came in at $7.63 million, compared to a loss from operations of $7.79 million in the prior year's quarter.
In addition, the company's non-GAAP net income amounted to $4.26 million, or $0.01 per share, compared to a net loss of $12.61 million, or $0.06 per share, in the same quarter of 2022, respectively.
Street expects MNKD's revenue for the fiscal year (ended December 2023) to increase 94.1% year-over-year to $193.64 million. However, analysts estimate that the company will report a loss per share of $0.05 for the same period.
Shares of MNKD have gained 1.8% over the past five days to close the last trading session at $3.41.
MNKD's mixed prospects are apparent in its POWR Ratings. The stock has an overall rating of C, which translates to a Neutral in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
MNKD has an A grade for Growth and a B for Value. It also has a C grade for Sentiment and Quality. It has ranked #40 out of 349 stocks in the Biotech industry.
Click here to see the other ratings of MNKD for Momentum and Stability.
About the Author: Mangeet Kaur Bouns
Mangeet's keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet's looks to help retail investors understand the underlying factors before making investment decisions.